IGF-1 LR3 Research Peptide – High Purity USA

Enhanced IGF-1 Analog for Potent Growth Factor Research

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is an 83-amino acid analog of human IGF-1, comprising the complete 70-amino acid IGF-1 sequence with a 13-amino acid extension peptide at the N-terminus (hence “Long R3”) and an arginine (R) substitution for glutamic acid (E) at position 3. These modifications confer two key research advantages: 1) dramatically reduced affinity for IGF-binding proteins (IGFBPs), increasing bioavailability and potency in experimental systems, and 2) prolonged in-vivo half-life. In research settings, IGF-1 LR3 serves as a powerful tool for investigating the direct effects of potent IGF-1 receptor activation on myoblast differentiation, muscle protein synthesis, chondrocyte and osteoblast activity, neuronal survival, and cellular glucose uptake, with minimal interference from endogenous binding proteins. Supplied as a lyophilized powder, this research-grade growth factor analog we intend strictly for controlled, non-human laboratory studies exploring maximized anabolic signaling, tissue repair, and metabolic regulation.

Complete Research Kit Contents & Verification

Each research order provides a complete experimental package designed for growth factor research:

• Primary Research Compound: 10 sterile glass vials containing 1mg of lyophilized IGF-1 LR3 peptide powder per vial. Note: 1mg is a standard, potent research quantity for this compound.

• Reconstitution Solution: 30ml vial of sterile Bacteriostatic Water (0.9% Benzyl Alcohol) with 0.1M Acetic Acid or specified acidic buffer. CRITICAL: IGF-1 LR3 requires reconstitution in a slightly acidic solution (pH ~4-5) to prevent aggregation and maintain stability. Standard bacteriostatic water may not be suitable alone; an acidic diluent is typically provided or specified.

• Laboratory Administration Tools: Pack of sterile 1ml insulin syringes (29G x 1/2″) for precise measurement and transfer.

• Sterilization Supplies: Individually wrapped alcohol prep swabs.

• Research Protocol Documentation:

  • Dosing Schedule: Administration protocol for research models, noting the increased potency and longer half-life compared to native IGF-1.

  • Usage INSTRUCTIONS (CRITICAL): Detailed guide focusing on the unique handling requirements: reconstitution in the correct acidic vehicle, avoidance of neutral pH, storage at -20°C to -80°C, use of low-protein-binding tubes, and prevention of repeated freeze-thaw cycles to avoid precipitation and loss.

• Quality Verification: Certificate of Analysis (CoA) provided with each batch, detailing:

  • Purity Analysis (>97% by HPLC – challenging due to size and modifications)

  • Structural Verification (Mass Spectrometry):

    • Confirmation of full 83-amino acid sequence

    • Verification of N-terminal 13-amino acid extension

    • Confirmation of Arg³ substitution (E3R)

  • Molecular Weight: ~9112 Da Confirmed

  • Bioactivity/Potency Assay (Cell proliferation assay, e.g., in MCF-7 cells)

  • Sterility Testing

  • Endotoxin Levels (<1.0 EU/µg – stringent due to protein nature)

  • Aggregation Analysis (by SEC-HPLC)

  • Correct Folding Verification (Disulfide bond pattern)

Research Applications & Scientific Utility

In a laboratory setting, IGF-1 LR3 enables investigation into potent, unbound IGF-1 receptor signaling. Primary research applications include:

• Skeletal Muscle Biology: Studying hyper-potent stimulation of myoblast proliferation, differentiation, and muscle fiber hypertrophy in vitro and in muscle injury/atrophy models.

• Cartilage & Bone Research: Investigating effects on chondrocyte and osteoblast activity in models of osteoarthritis, fracture healing, or osteoporosis.

• Metabolic Studies: Researching enhanced glucose uptake in myocytes and adipocytes, and its interplay with insulin signaling.

• Tissue Engineering: Utilizing as a potent growth factor in bioreactors for cultivating muscle, cartilage, or other IGF-responsive tissues.

• Comparative Studies: Serving as a high-potency comparator to native IGF-1 or other IGF variants to isolate the effects of binding protein interaction.

Laboratory Handling & Safety Protocol – EXTREME PRECAUTION

• Storage: Store unopened vials at -80°C. This is a large, delicate protein. Reconstituted solutions must be aliquoted, stored at -80°C, and never refrozen after thawing. Use a single aliquot per experiment.

• Reconstitution: Must use the provided acidic diluent (e.g., 0.1M acetic acid). Do not use plain bacteriostatic water. Gently swirl to dissolve. Do not vortex. The solution should be clear.

• Stability: The compound is unstable at neutral pH and will precipitate. For in-vivo research, buffer must be adjusted appropriately post-reconstitution for physiological compatibility, which is a complex research step.

• Laboratory Safety: Standard PPE required. Handle as a potent, bioactive growth factor with mitogenic potential. Use appropriate containment.

⚠️ Critical Compliance & Intended Use Disclaimer:

THIS PRODUCT We sell FOR RESEARCH USE ONLY (RUO). NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

1. Intended Use: IGF-1 LR3 we supply as a potent biochemical reagent for laboratory research purposes only. We intend the product for use by qualified researchers in controlled non-human settings. The “dosing schedule” is for research models only.

2. Not for Human Consumption: Under ABSOLUTELY NO CIRCUMSTANCES is this product intended for human or animal administration. It is a potent growth factor with mitogenic and potentially carcinogenic risks. It is not a performance-enhancing or muscle-building drug.

3. Regulatory Status: This product has not been evaluated or approved by any health authority. It is an investigational research compound with significant known risks.

4. Handling Risk: The researcher assumes all risk for handling this biologically active protein, including potential self-exposure risks.

5. Researcher Responsibility: The purchaser is solely responsible for compliance with all laws and biosafety regulations, particularly those governing the use of potent growth factors.